Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
3.360
-0.020 (-0.59%)
May 12, 2026, 11:47 AM EDT - Market open
Company Description
Exicure, Inc. does not have significant operations.
Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.
Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Exicure, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Jungsoo Kim |
Contact Details
Address: 400 Seaport Court, Suite 102 Redwood City, California 94063 United States | |
| Phone | 847 673 1700 |
| Website | exicuretx.com |
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1698530 |
| CUSIP Number | 30205M101 |
| ISIN Number | US30205M3097 |
| Employer ID | 81-5333008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jungsoo Kim | Chief Executive Officer, President and Director |
| Gyuyeob Lee | Interim Chief Financial Officer and Secretary |
| Young Seung Ko | Chief Operating Officer |
| Joshua Miller | Chief Accounting Officer |
| Dr. Devki Sukhtankar Ph.D. | Head of Preclinical Research and Translational Medicine |
| Dr. Niña Caculitan Ph.D. | Head of Clinical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2026 | 8-K | Current Report |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 25, 2026 | 10-K | Annual Report |
| Mar 25, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 10, 2026 | 8-K | Current Report |
| Jan 22, 2026 | 8-K | Current Report |
| Jan 21, 2026 | SCHEDULE 13D/A | Filing |
| Jan 20, 2026 | SCHEDULE 13D/A | Filing |